{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:16:17Z","timestamp":1793394977688,"version":"4.5.0"},"reference-count":145,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.ctrv.2019.101911","type":"journal-article","created":{"date-parts":[[2019,11,2]],"date-time":"2019-11-02T04:32:40Z","timestamp":1572669160000},"page":"101911","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":242,"special_numbering":"C","title":["RET fusions in solid tumors"],"prefix":"10.1016","volume":"81","author":[{"given":"Andrew Y.","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8547-8860","authenticated-orcid":false,"given":"Michael G.","family":"McCusker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3365-1972","authenticated-orcid":false,"given":"Alessandro","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Scilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Gittens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Arensmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranee","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Adamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Rolfo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2019.101911_b0005","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/0092-8674(85)90115-1","article-title":"Activation of a novel human transforming gene, ret, by DNA rearrangement","volume":"42","author":"Takahashi","year":"1985","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2019.101911_b0010","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.cellsig.2004.10.012","article-title":"Direct interactions among Ret, GDNF and GFRalpha1 molecules reveal new insights into the assembly of a functional three-protein complex","volume":"17","author":"Amoresano","year":"2005","journal-title":"Cell Signal"},{"key":"10.1016\/j.ctrv.2019.101911_b0015","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1016\/j.bbapap.2012.10.008","article-title":"Structural studies of GDNF family ligands with their receptors-Insights into ligand recognition and activation of receptor tyrosine kinase RET","volume":"1834","author":"Wang","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.ctrv.2019.101911_b0020","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.cytogfr.2005.05.010","article-title":"RET tyrosine kinase signaling in development and cancer","volume":"16","author":"Arighi","year":"2005","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.ctrv.2019.101911_b0025","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0896-6273(00)81064-8","article-title":"GFRalpha-mediated localization of RET to lipid rafts is required for effective downstream signaling, differentiation, and neuronal survival","volume":"25","author":"Tansey","year":"2000","journal-title":"Neuron"},{"key":"10.1016\/j.ctrv.2019.101911_b0030","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009134","article-title":"Structure and physiology of the RET receptor tyrosine kinase","volume":"5","author":"Ib\u00e1\u00f1ez","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.ctrv.2019.101911_b0035","doi-asserted-by":"crossref","first-page":"39159","DOI":"10.1074\/jbc.M006908200","article-title":"Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase","volume":"275","author":"Besset","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ctrv.2019.101911_b0040","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1074\/jbc.M107992200","article-title":"Coordinated activation of autophosphorylation sites in the RET receptor tyrosine kinase: importance of tyrosine 1062 for GDNF mediated neuronal differentiation and survival","volume":"277","author":"Coulpier","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ctrv.2019.101911_b0045","first-page":"3727","article-title":"Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival","volume":"60","author":"De Vita","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2019.101911_b0050","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1038\/sj.onc.1203799","article-title":"Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor","volume":"19","author":"Hayashi","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2019.101911_b0055","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0304-3835(03)00456-7","article-title":"RET and neuroendocrine tumors","volume":"204","author":"Ichihara","year":"2004","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ctrv.2019.101911_b0060","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1074\/jbc.275.5.3568","article-title":"Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol","volume":"275","author":"Segouffin-Cariou","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ctrv.2019.101911_b0065","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1101\/gad.1387206","article-title":"Critical and distinct roles for key RET tyrosine docking sites in renal development","volume":"20","author":"Jain","year":"2006","journal-title":"Genes Dev"},{"key":"10.1016\/j.ctrv.2019.101911_b0070","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2443.2008.01171.x","article-title":"GDNF-mediated signaling via RET tyrosine 1062 is essential for maintenance of spermatogonial stem cells","volume":"13","author":"Jijiwa","year":"2008","journal-title":"Genes Cells"},{"key":"10.1016\/j.ctrv.2019.101911_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jmg.2007.053959","article-title":"Hirschsprung disease, associated syndromes and genetics: a review","volume":"45","author":"Amiel","year":"2008","journal-title":"J Med Genet"},{"key":"10.1016\/j.ctrv.2019.101911_b0080","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/367378a0","article-title":"Mutations of the RET proto-oncogene in Hirschsprung\u2019s disease","volume":"367","author":"Edery","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2019.101911_b0085","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/367377a0","article-title":"Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung\u2019s disease","volume":"367","author":"Romeo","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2019.101911_b0090","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00467-013-2606-5","article-title":"To bud or not to bud: the RET perspective in CAKUT","volume":"29","author":"Davis","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ctrv.2019.101911_b0095","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/hmg\/2.7.851","article-title":"Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC","volume":"2","author":"Donis-Keller","year":"1993","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.ctrv.2019.101911_b0100","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/363458a0","article-title":"Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A","volume":"363","author":"Mulligan","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2019.101911_b0105","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/367375a0","article-title":"A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma","volume":"367","author":"Hofstra","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2019.101911_b0110","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrc3680","article-title":"RET revisited: expanding the oncogenic portfolio","volume":"14","author":"Mulligan","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2019.101911_b0115","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1056\/NEJMoa020152","article-title":"Germ-line mutations in nonsyndromic pheochromocytoma","volume":"346","author":"Neumann","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2019.101911_b0120","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1158\/0008-5472.CAN-12-4265","article-title":"GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors","volume":"73","author":"Morandi","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2019.101911_b0125","doi-asserted-by":"crossref","first-page":"11732","DOI":"10.1158\/0008-5472.CAN-07-2343","article-title":"A role for glial cell derived neurotrophic factor induced expression by inflammatory cytokines and RET\/GFR alpha 1 receptor up-regulation in breast cancer","volume":"67","author":"Esseghir","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2019.101911_b0130","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1038\/onc.2010.209","article-title":"Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance","volume":"29","author":"Plaza-Menacho","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2019.101911_b0135","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/emmm.201302625","article-title":"Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells","volume":"5","author":"Gattelli","year":"2013","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.ctrv.2019.101911_b0140","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1002\/ijc.29974","article-title":"Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers","volume":"138","author":"Hatem","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2019.101911_b0145","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1158\/0008-5472.CAN-07-5100","article-title":"The Ret receptor tyrosine kinase pathway functionally interacts with the ERalpha pathway in breast cancer","volume":"68","author":"Boulay","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2019.101911_b0150","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1677\/erc.1.01120","article-title":"Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach","volume":"13","author":"Tozlu","year":"2006","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ctrv.2019.101911_b0155","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/1078-0432.CCR-13-2221","article-title":"Inhibition of RET increases the efficacy of antiestrogen and is a novel treatment strategy for luminal breast cancer","volume":"20","author":"Spanheimer","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2019.101911_b0160","doi-asserted-by":"crossref","first-page":"80543","DOI":"10.18632\/oncotarget.11826","article-title":"Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts","volume":"7","author":"Andreucci","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2019.101911_b0165","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/onc.2012.225","article-title":"RET is a potential tumor suppressor gene in colorectal cancer","volume":"32","author":"Luo","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2019.101911_b0170","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13046-018-0746-y","article-title":"Next-generation sequencing analysis of receptor-type tyrosine kinase genes in surgically resected colon cancer: identification of gain-of-function mutations in the RET proto-oncogene","volume":"37","author":"Mendes Oliveira","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2019.101911_b0175","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.surg.2005.07.007","article-title":"Expression of glial cell line-derived neurotrophic factor family members and their receptors in pancreatic cancers","volume":"138","author":"Ito","year":"2005","journal-title":"Surgery"},{"key":"10.1016\/j.ctrv.2019.101911_b0180","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1177\/147323000803600406","article-title":"The relationship between overexpression of glial cell-derived neurotrophic factor and its RET receptor with progression and prognosis of human pancreatic cancer","volume":"36","author":"Zeng","year":"2008","journal-title":"J Int Med Res"},{"key":"10.1016\/j.ctrv.2019.101911_b0185","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1038\/onc.2016.483","article-title":"Upregulation of RET induces perineurial invasion of pancreatic adenocarcinoma","volume":"36","author":"Amit","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2019.101911_b0190","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.urolonc.2010.08.025","article-title":"RET protein expression in papillary renal cell carcinoma","volume":"30","author":"Flavin","year":"2012","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ctrv.2019.101911_b0195","doi-asserted-by":"crossref","first-page":"6870470","DOI":"10.1155\/2016\/6870470","article-title":"Prognostic and predictive values of subcellular localisation of RET in renal clear-cell carcinoma","volume":"2016","author":"Wang","year":"2016","journal-title":"Dis Markers"},{"key":"10.1016\/j.ctrv.2019.101911_b0200","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/jnci\/90.7.519","article-title":"Altered expression of RET proto-oncogene product in prostatic intraepithelial neoplasia and prostate cancer","volume":"90","author":"Dawson","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2019.101911_b0205","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1158\/1078-0432.CCR-17-0528","article-title":"RET signaling in prostate cancer","volume":"23","author":"Ban","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2019.101911_b0210","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1038\/onc.2009.164","article-title":"Functional RET G691S polymorphism in cutaneous malignant melanoma","volume":"28","author":"Narita","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2019.101911_b0215","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaad.2016.04.059","article-title":"Ki-67, p53, and p16 expression, and G691S RET polymorphism in desmoplastic melanoma (DM): A clinicopathologic analysis of predictors of outcome","volume":"75","author":"Lawrence","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ctrv.2019.101911_b0220","doi-asserted-by":"crossref","first-page":"e10279","DOI":"10.1371\/journal.pone.0010279","article-title":"c-RET molecule in malignant melanoma from oncogenic RET-carrying transgenic mice and human cell lines","volume":"5","author":"Ohshima","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2019.101911_b0225","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1097\/JTO.0000000000000234","article-title":"RET mutation and expression in small-cell lung cancer","volume":"9","author":"Dabir","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2019.101911_b0230","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/modpathol.2016.48","article-title":"Expression profiling of small intestinal neuroendocrine tumors identifies subgroups with clinical relevance, prognostic markers and therapeutic targets","volume":"29","author":"Andersson","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ctrv.2019.101911_b0235","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.lungcan.2013.07.009","article-title":"Diagnostic method for the detection of KIF5B-RET transformation in lung adenocarcinoma","volume":"82","author":"Go","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2019.101911_b0240","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4614-7001-4","author":"Wong","year":"2013","journal-title":"Next Generation Sequencing"},{"key":"10.1016\/j.ctrv.2019.101911_b0245","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jmoldx.2014.03.006","article-title":"Detection of gene rearrangements in targeted clinical next-generation sequencing","volume":"16","author":"Abel","year":"2014","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.ctrv.2019.101911_b0250","doi-asserted-by":"crossref","first-page":"8049","DOI":"10.1200\/jco.2014.32.15_suppl.8049","article-title":"Identifying ALK rearrangements that are not detected by FISH with targeted next-generation sequencing of lung carcinoma","volume":"32","author":"Ali","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.101911_b0255","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1158\/1078-0432.CCR-14-2683","article-title":"Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in lung adenocarcinomas otherwise negative for such alterations by other genomic testing approaches","volume":"21","author":"Drilon","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2019.101911_b0260","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.ctrv.2019.101911_b0265","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.lungcan.2014.03.002","article-title":"Sensitive and specific detection of EML4-ALK rearrangements in non-small cell lung cancer (NSCLC) specimens by multiplex amplicon RNA massive parallel sequencing","volume":"84","author":"Moskalev","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2019.101911_b0270","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1634\/theoncologist.2014-0389","article-title":"Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer","volume":"20","author":"Pekar-Zlotin","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2019.101911_b0275","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/nm.3729","article-title":"Anchored multiplex PCR for targeted next-generation sequencing","volume":"20","author":"Zheng","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2019.101911_b0280","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jmoldx.2015.10.002","article-title":"A Multiplexed Amplicon Approach for Detecting Gene Fusions by Next-Generation Sequencing","volume":"18","author":"Beadling","year":"2016","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.ctrv.2019.101911_b0285","doi-asserted-by":"crossref","first-page":"R115","DOI":"10.1186\/gb-2009-10-10-r115","article-title":"Targeted next-generation sequencing of a cancer transcriptome enhances detection of sequence variants and novel fusion transcripts","volume":"10","author":"Levin","year":"2009","journal-title":"Genome Biol"},{"key":"10.1016\/j.ctrv.2019.101911_b0290","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.jmoldx.2017.05.006","article-title":"Validation of a targeted RNA sequencing assay for kinase fusion detection in solid tumors","volume":"19","author":"Reeser","year":"2017","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.ctrv.2019.101911_b0295","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41568-018-0043-2","article-title":"Clinical tumour sequencing for precision oncology: time for a universal strategy","volume":"18","author":"Cheng","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2019.101911_b0300","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-19-0225","article-title":"High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden","author":"Benayed","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2019.101911_b0305","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.jtho.2018.05.030","article-title":"Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC","volume":"13","author":"Rolfo","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2019.101911_b0310","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-18-4049","article-title":"Analysis of cell-free DNA from 32,989 advanced cancers reveals novel co-occurring activating RET alterations and oncogenic signaling pathway aberrations","author":"Rich","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2019.101911_b0315","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.lungcan.2019.06.004","article-title":"Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA","volume":"134","author":"Supplee","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2019.101911_b0320","first-page":"1170","article-title":"The ret\/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults","volume":"85","author":"Fenton","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2019.101911_b0325","first-page":"3211","article-title":"RET\/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults","volume":"86","author":"Elisei","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2019.101911_b0330","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1210\/jcem.86.5.7504","article-title":"Analysis of ret\/PTC gene rearrangements refines the fine needle aspiration diagnosis of thyroid cancer","volume":"86","author":"Cheung","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2019.101911_b0335","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1385\/EP:13:1:03","article-title":"RET\/PTC rearrangement in thyroid tumors","volume":"13","author":"Nikiforov","year":"2002","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.ctrv.2019.101911_b0340","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3389\/fendo.2012.00054","article-title":"RET\/PTC translocations and clinico-pathological features in human papillary thyroid carcinoma","volume":"3","author":"Romei","year":"2012","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.ctrv.2019.101911_b0345","doi-asserted-by":"crossref","first-page":"E1758","DOI":"10.1210\/jc.2012-1269","article-title":"Modifications in the papillary thyroid cancer gene profile over the last 15 years","volume":"97","author":"Romei","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2019.101911_b0350","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1210\/jc.2014-4153","article-title":"RET fusion as a novel driver of medullary thyroid carcinoma","volume":"100","author":"Grubbs","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2019.101911_b0355","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nrendo.2016.11","article-title":"A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma","volume":"12","author":"Romei","year":"2016","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ctrv.2019.101911_b0360","doi-asserted-by":"crossref","first-page":"45784","DOI":"10.18632\/oncotarget.17412","article-title":"Targeted next generation sequencing identifies somatic mutations and gene fusions in papillary thyroid carcinoma","volume":"8","author":"Lu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2019.101911_b0365","doi-asserted-by":"crossref","unstructured":"Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014; 159: 676\u201390. https:\/\/doi.org\/10.1016\/j.cell.2014.09.050.","DOI":"10.1016\/j.cell.2014.09.050"},{"key":"10.1016\/j.ctrv.2019.101911_b0370","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/sj.onc.1200206","article-title":"High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation","volume":"15","author":"Bounacer","year":"1997","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2019.101911_b0375","doi-asserted-by":"crossref","first-page":"7176","DOI":"10.1158\/0008-5472.CAN-08-0293","article-title":"RET\/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose","volume":"68","author":"Hamatani","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2019.101911_b0380","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.3892\/or.2014.3449","article-title":"Kusunoki Y. A novel RET rearrangement (ACBD5\/RET) by pericentric inversion, inv(10)(p12.1;q11.2), in papillary thyroid cancer from an atomic bomb survivor exposed to high-dose radiation","volume":"32","author":"Hamatani","year":"2014","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ctrv.2019.101911_b0385","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/cncr.27893","article-title":"RET\/PTC and PAX8\/PPARgamma chromosomal rearrangements in post-Chernobyl thyroid cancer and their association with iodine-131 radiation dose and other characteristics","volume":"119","author":"Leeman-Neill","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2019.101911_b0390","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1172\/JCI69766","article-title":"Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers","volume":"123","author":"Ricarte-Filho","year":"2013","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.ctrv.2019.101911_b0395","first-page":"53","article-title":"ret\/PTC-1, -2, and -3 Incogene Rearrangements of Papillary Thyroid Carcinomas in Korea and Its Relevance to Clinical Aggressiveness","volume":"14","author":"Chung","year":"1999","journal-title":"Endocrinol Metabol"},{"key":"10.1016\/j.ctrv.2019.101911_b0400","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.surg.2018.08.029","article-title":"Genetic characterization of medullary thyroid cancer in childhood survivors of the Chernobyl accident","volume":"165","author":"Fisher","year":"2019","journal-title":"Surgery"},{"key":"10.1016\/j.ctrv.2019.101911_b0405","first-page":"1690","article-title":"Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children","volume":"57","author":"Nikiforov","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2019.101911_b0410","first-page":"5523","article-title":"The RET\/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids","volume":"58","author":"Powell","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2019.101911_b0415","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0039-6060(99)70287-4","article-title":"Oncogene profile of papillary thyroid carcinoma","volume":"125","author":"Sugg","year":"1999","journal-title":"Surgery"},{"key":"10.1016\/j.ctrv.2019.101911_b0420","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1365-2559.2006.02555.x","article-title":"Clinical significance of RET\/PTC and p53 protein expression in sporadic papillary thyroid carcinoma","volume":"50","author":"Zafon","year":"2007","journal-title":"Histopathology"},{"key":"10.1016\/j.ctrv.2019.101911_b0425","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1365-2559.2010.03646.x","article-title":"RET rearrangements and BRAF mutation in undifferentiated thyroid carcinomas having papillary carcinoma components","volume":"57","author":"Mochizuki","year":"2010","journal-title":"Histopathology"},{"key":"10.1016\/j.ctrv.2019.101911_b0430","first-page":"287","article-title":"RET\/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes","volume":"4","author":"Tallini","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2019.101911_b0435","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1067\/msy.2000.110845","article-title":"Prognostic significance of RET and NTRK1 rearrangements in sporadic papillary thyroid carcinoma","volume":"128","author":"Musholt","year":"2000","journal-title":"Surgery"},{"key":"10.1016\/j.ctrv.2019.101911_b0440","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1530\/eje.0.1450599","article-title":"RET protein expression has no prognostic impact on the long-term outcome of papillary thyroid carcinoma","volume":"145","author":"Basolo","year":"2001","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ctrv.2019.101911_b0445","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1530\/eje.0.1480505","article-title":"Ret\/PTC activation does not influence clinical and pathological features of adult papillary thyroid carcinomas","volume":"148","author":"Puxeddu","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ctrv.2019.101911_b0450","first-page":"87","article-title":"[Expressions of wildtype-RET and RET\/PTC rearrangements in sporadic adult papillary thyroid carcinoma and their clinicopathologic correlation]","volume":"35","author":"Zhu","year":"2006","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"10.1016\/j.ctrv.2019.101911_b0455","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1677\/ERC-07-0130","article-title":"BRAFV600E mutation, but not RET\/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer","volume":"15","author":"Romei","year":"2008","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ctrv.2019.101911_b0460","doi-asserted-by":"crossref","first-page":"171","DOI":"10.4103\/0022-3859.57390","article-title":"Prevalence of RET\/PTC expression in papillary thyroid carcinoma and its correlation with prognostic factors in a north Indian population","volume":"55","author":"Mishra","year":"2009","journal-title":"J Postgrad Med"},{"key":"10.1016\/j.ctrv.2019.101911_b0465","first-page":"435","article-title":"RET\/PTC rearrangement affects multifocal formation of papillary thyroid carcinoma","volume":"52","author":"Zhang","year":"2017","journal-title":"Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi"},{"key":"10.1016\/j.ctrv.2019.101911_b0470","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1097\/JTO.0000000000000301","article-title":"RET mutations in neuroendocrine tumors: including small-cell lung cancer","volume":"9","author":"Rudin","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2019.101911_b0475","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nm.2644","article-title":"KIF5B-RET fusions in lung adenocarcinoma","volume":"18","author":"Kohno","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2019.101911_b0480","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/cr.2012.27","article-title":"Identification of RET gene fusion by exon array analyses in \u201cpan-negative\u201d lung cancer from never smokers","volume":"22","author":"Li","year":"2012","journal-title":"Cell Res"},{"key":"10.1016\/j.ctrv.2019.101911_b0485","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nm.2673","article-title":"Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies","volume":"18","author":"Lipson","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2019.101911_b0490","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nm.2658","article-title":"RET, ROS1 and ALK fusions in lung cancer","volume":"18","author":"Takeuchi","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2019.101911_b0495","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3346\/jkms.2013.28.10.1555","article-title":"RET fusion genes in Korean non-small cell lung cancer","volume":"28","author":"Yoo","year":"2013","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.ctrv.2019.101911_b0500","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1080\/15384047.2015.1046649","article-title":"The RET fusion gene and its correlation with demographic and clinicopathological features of non-small cell lung cancer: a meta-analysis","volume":"16","author":"Lin","year":"2015","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.ctrv.2019.101911_b0505","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1158\/1078-0432.CCR-16-1679","article-title":"RET aberrations in diverse cancers: next-generation sequencing of 4871 patients","volume":"23","author":"Kato","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2019.101911_b0510","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1200\/JCO.2012.44.1477","article-title":"RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer","volume":"30","author":"Wang","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.101911_b0515","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1101\/gr.133645.111","article-title":"A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing","volume":"22","author":"Ju","year":"2012","journal-title":"Genome Res"},{"key":"10.1016\/j.ctrv.2019.101911_b0520","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1016\/j.cllc.2016.09.003","article-title":"RET fusion lung carcinoma: response to therapy and clinical features in a case series of 14 patients","volume":"18","author":"Sarfaty","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctrv.2019.101911_b0525","first-page":"1403","article-title":"Targeting RET in patients with RET-rearranged lung cancers: results from the global","volume":"35","author":"Gautschi","year":"2017","journal-title":"Multicenter RET Registry. J Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.101911_b0530","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1016\/j.celrep.2016.08.019","article-title":"Drosophila cancer models identify functional differences between ret fusions","volume":"16","author":"Levinson","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.ctrv.2019.101911_b0535","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/sj.leu.2404154","article-title":"Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia","volume":"20","author":"Score","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2019.101911_b0540","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1158\/1078-0432.CCR-08-3248","article-title":"KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer","volume":"15","author":"Takeuchi","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2019.101911_b0545","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.lungcan.2015.06.021","article-title":"Emergence of RET rearrangement co-existing with activated EGFR mutation in","volume":"89","author":"Klempner","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2019.101911_b0550","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3349\/ymj.2017.58.1.9","article-title":"EGF induced RET inhibitor resistance in CCDC6-RET lung cancer cells","volume":"58","author":"Chang","year":"2017","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.ctrv.2019.101911_b0555","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1158\/2159-8290.CD-18-1022","article-title":"Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion","volume":"8","author":"Piotrowska","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2019.101911_b0560","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1093\/annonc\/mdw163","article-title":"Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers","volume":"27","author":"Drilon","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2019.101911_b0565","article-title":"Immunophenotype and response to immunotherapy of RET-rearranged lung cancers","volume":"3","author":"Offin","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ctrv.2019.101911_b0570","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.canlet.2008.02.018","article-title":"Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement","volume":"265","author":"Ogino","year":"2008","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ctrv.2019.101911_b0575","doi-asserted-by":"crossref","first-page":"28929","DOI":"10.18632\/oncotarget.4325","article-title":"Identification and characterization of RET fusions in advanced colorectal cancer","volume":"6","author":"Le Rolle","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2019.101911_b0580","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.7150\/jca.26256","article-title":"NCOA4-RET fusion in colorectal cancer: therapeutic challenge using patient-derived tumor cell lines","volume":"9","author":"Kim","year":"2018","journal-title":"J Cancer"},{"key":"10.1016\/j.ctrv.2019.101911_b0585","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1093\/annonc\/mdy090","article-title":"RET fusions in a small subset of advanced colorectal cancers at risk of being neglected","volume":"29","author":"Pietrantonio","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2019.101911_b0590","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1038\/s41467-018-07341-4","article-title":"RET rearrangements are actionable alterations in breast cancer","volume":"9","author":"Paratala","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2019.101911_b0595","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1210\/jc.2002-021278","article-title":"Efficient inhibition of RET\/papillary thyroid carcinoma oncogenic kinases by","volume":"88","author":"Carlomagno","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2019.101911_b0600","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1530\/EC-15-0098","article-title":"Destabilizing RET in targeted treatment of thyroid cancers","volume":"5","author":"Gild","year":"2016","journal-title":"Endocr Connect"},{"key":"10.1016\/j.ctrv.2019.101911_b0605","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1158\/2159-8290.CD-18-0839","article-title":"A Phase I\/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105","volume":"9","author":"Drilon","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2019.101911_b0610","unstructured":"Drilon A, Oxnard GR, Wirth L, Besse B, Gautchi O, Tan DS, et al. PL02.08 Registrational results of LIBRETTO-001: A phase 1\/2 trial of LOXO-292 in patients with RET fusion-positive lung cancers. Presented at: IASLC 2019 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer; September 7-10, 2019; Barcelona, Spain. Abstract PL02.08."},{"key":"10.1016\/j.ctrv.2019.101911_b0615","doi-asserted-by":"crossref","first-page":"9008","DOI":"10.1200\/JCO.2019.37.15_suppl.9008","article-title":"Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC)","volume":"37","author":"Gainor","year":"2019","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ctrv.2019.101911_b0620","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.lungcan.2015.12.011","article-title":"Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer","volume":"93","author":"Horiike","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2019.101911_b0625","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1097\/JTO.0b013e3182721ed1","article-title":"Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line","volume":"7","author":"Matsubara","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2019.101911_b0630","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1158\/1535-7163.MCT-17-0008","article-title":"Resistance to RET-inhibition in RET-rearranged NSCLC Is Mediated By reactivation of RAS\/MAPK signaling","volume":"16","author":"Nelson-Taylor","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2019.101911_b0635","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.canlet.2013.07.007","article-title":"Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models","volume":"340","author":"Okamoto","year":"2013","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ctrv.2019.101911_b0640","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4161\/cbt.12.5.16303","article-title":"Sunitinib inhibits papillary thyroid carcinoma with RET\/PTC rearrangement but not BRAF mutation","volume":"12","author":"Jeong","year":"2011","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.ctrv.2019.101911_b0645","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1158\/1535-7163.MCT-14-0274","article-title":"Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer","volume":"13","author":"Kodama","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2019.101911_b0650","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1158\/1078-0432.CCR-16-1887","article-title":"Antitumor activity of RXDX-105 in multiple cancer types with RET rearrangements or mutations","volume":"23","author":"Li","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2019.101911_b0655","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S1470-2045(16)30562-9","article-title":"Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial","volume":"17","author":"Drilon","year":"2016","journal-title":"Lancet Oncol"},{"issue":"suppl_6","key":"10.1016\/j.ctrv.2019.101911_b0660","first-page":"1204PD","article-title":"Phase 2 study of lenvatinib (LN) in patients (Pts) with RET fusion-positive adenocarcinoma of the lung","volume":"27","author":"Velcheti","year":"2016","journal-title":"Ann Oncol."},{"key":"10.1016\/j.ctrv.2019.101911_b0665","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/annonc\/mdw559","article-title":"Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial","volume":"28","author":"Lee","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2019.101911_b0670","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S2213-2600(16)30322-8","article-title":"Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial","volume":"5","author":"Yoh","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ctrv.2019.101911_b0675","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy292.108","article-title":"1487P LURET: Final survival results of the phase II trial of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer","volume":"29","author":"Yoh","year":"2018","journal-title":"Annals Oncol"},{"key":"10.1016\/j.ctrv.2019.101911_b0680","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2152\/jmi.64.317","article-title":"Phase I\/II study of alectinib in lung cancer with RET fusion gene: study protocol","volume":"64","author":"Takeuchi","year":"2017","journal-title":"J Med Invest"},{"key":"10.1016\/j.ctrv.2019.101911_b0685","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1158\/2159-8290.CD-18-0338","article-title":"Precision targeted therapy with BLU-667 for RET-driven cancers","volume":"8","author":"Subbiah","year":"2018","journal-title":"Cancer Discov"},{"issue":"suppl_5","key":"10.1016\/j.ctrv.2019.101911_b0690","first-page":"v605","article-title":"LBA19A phase 1b study of RXDX-105, a VEGFR-sparing potent RET inhibitor, in RETi-na\u00efve patients with RET fusion-positive NSCLC","volume":"28","author":"Drilon","year":"2017","journal-title":"Ann Oncol."},{"key":"10.1016\/j.ctrv.2019.101911_b0695","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2017.12.021","article-title":"Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers","volume":"128","author":"Roskoski","year":"2018","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ctrv.2019.101911_b0700","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1021\/ml500402t","article-title":"RET kinase inhibitors may treat cancer and gastrointestinal disorders","volume":"6","author":"Abdel-Magid","year":"2014","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.ctrv.2019.101911_b0705","doi-asserted-by":"crossref","first-page":"T53","DOI":"10.1530\/ERC-17-0297","article-title":"Novel targeted therapeutics for MEN2","volume":"25","author":"Redaelli","year":"2018","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2019.101911_b0710","first-page":"22","article-title":"Selective RET inhibitor, BLU-667, hits the target in patients with lung or thyroid cancers","volume":"9","author":"Starr","year":"2018","journal-title":"Value-Based Cancer Care"},{"key":"10.1016\/j.ctrv.2019.101911_b0715","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1200\/JCO.2019.37.15_suppl.6018","article-title":"Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers","volume":"37","author":"Taylor","year":"2019","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ctrv.2019.101911_b0720","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/JTO.0000000000000015","article-title":"RET rearrangements in lung adenocarcinoma and radiation","volume":"9","author":"Dacic","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2019.101911_b0725","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz394.093","article-title":"LBA93Registrational results of LOXO-292 in patients with RET-altered thyroid cancers","volume":"30","author":"Wirth","year":"2019","journal-title":"Ann Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573721930129X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573721930129X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:21:43Z","timestamp":1759656103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030573721930129X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":145,"alternative-id":["S030573721930129X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2019.101911","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RET fusions in solid tumors","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2019.101911","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101911"}}